Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Standard Practice in NIV
NCT02958150Phase 4Unknown
- Sponsor
- Osakidetza
- Start
- Oct 2016
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexmedetomidine in acute respiratory failure (ARF) (2 arms), sponsored by Osakidetza. Primary endpoint: Percentage of orotracheal intubations at 72 hours. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
acute respiratory failure (ARF)
Beyond the preview
Go deeper on NCT02958150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958150.